Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.doi:10.1200/JCO.2024.42.16_suppl.555945559#Background:The open-label, single-arm, L-MOCA trial (NCT03534453) was the first study...
The standard of care in relapsed ovarian cancer typically is treatment with systemic chemotherapy. But in a recenttrial, women with recurrent ovarian cancer had longer overall survival when they had secondary cytoreductive surgery followed by chemotherapy instead of chemotherapy alone. ...
et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J. Clin. Oncol. 41, 609–617 (2022). Gonzalez-Martin, A. et al. Niraparib in patients with newly diagnosed ...
[6] Pereira A, Pérez-Medina T,MagrinaJ F, et al. The impact ofdebulkingsurgery in patients with node-positive epithelial ovarian cancer: analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period[J]. Surgical Oncology, ...
case–control studies from the Ovarian Cancer Association Consortium (OCAC), we sought to evaluate the association between BMI and survival (PFS, ovarian cancer-specific and overall survival (OS)), overall and by histologic subtype, in over 12 000 women with invasive epithelial ovarian cancer. ...
Trial evaluating overall survival in epithelial ovarian cancer (eoc) patients in second remission with an autologous dendritic cell therapy targeting mucin 1Genotype VIId Newcastle disease virusGeneticPhenotypicGeeseChickensNo Abstract available for this article....
The objective of this study was to examine the relationship between dominance (a surrogate for site of origin) and survival, following a diagnosis of epithelial ovarian cancer. Methods We classified 1,386 tumors as dominant (putatively originating in the ovary) and non-dominant (putatively ...
Aims Ovarian cancer is the principal cause of gynaecological cancer death in developed countries, yet overall survival in the UK has been reported as being inferior to that in some Western countries. As there is a range of survival across the UK we hypothesised that in major regional centres, ...
ent ovarian cancer. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.nomogram
women with advanced-stage epithelial ovarian cancer and uses three prognostic variables: preoperative haemoglobin serum concentra- tions (mmol l À 1), preoperative blood platelet counts (109 l À 1) and postoperative residual tumour (o1 cm), to predict 5-year overall survival (OS) probability...